FY2022 · ended Mar 31, 2022 · Revenue $100.00M, +50920.4% YoY · Filed Jun 23, 2023
Grace Therapeutics, Inc. (GRCE) files with the SEC under industry code 2834, Pharmaceutical Preparations.
Revenue
$100.00M
+50920.4% vs prior year
Net income
$-7.79M
+18.6% vs prior year
Operating cash flow (TTM)
$-10.29M
Free cash flow
—
EPS
$-0.47
+40.5% vs prior year
Dividend per share
None
Shares outstanding
16.27M
+17.7% vs prior year
Net cash
$23.00M
FY 2024
Operating margin
-15.6%
FY 2022
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- GRCE (Nasdaq)
- Fiscal year ends
- March 31
- Incorporated in
- DE
- Headquarters
- Princeton, NJ
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1444192
- Former names
- Acasti Pharma Inc. (until Oct 25, 2024)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2026 Mar 31, 2026 |
FY 2025 Mar 31, 2025 |
FY 2024 Mar 31, 2024 |
FY 2023 Mar 31, 2023 |
FY 2022 Mar 31, 2022 |
|---|---|---|---|---|---|
| Revenue | — | — | — | — | $100.0M |
| Operating income | -$11.1M | -$16.7M | -$12.9M | -$52.2M | -$15.6M |
| Net income | -$7.8M | -$9.6M | -$12.9M | -$42.4M | -$9.8M |
| Diluted EPS | -$0.47 | -$0.79 | -$1.35 | -$5.71 | — |
| Operating cash flow | -$8.9M | -$14.9M | -$12.3M | -$15.9M | -$17.2M |
| Total assets | $66.7M | $72.0M | $73.3M | $79.1M | $128.6M |
| Total liabilities | $2.8M | $5.4M | $11.6M | $11.2M | $20.4M |
| Stockholders' equity | $63.9M | $66.6M | $61.7M | $68.0M | $108.3M |
| Cash and investments | $17.0M | $22.1M | $23.0M | $27.9M | $43.7M |
| Total debt | — | — | $0 | $485,000 | $295,000 |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Shareholder vote results
|
Sep 18, 2026 | Sep 17, 2026 |
| 8-K |
Current report
Results of operations
|
Aug 13, 2026 | Aug 13, 2026 |
| 10-Q | Quarterly report | Aug 13, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Material agreement, Unregistered share sale, Other events
|
Aug 6, 2026 | Aug 4, 2026 |
| 8-K |
Current report
Other events
|
Jul 28, 2026 | Jul 28, 2026 |
| 8-K |
Current report
Other events
|
Jun 18, 2026 | Jun 18, 2026 |
All 593 Grace Therapeutics, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.